汇宇制药：多个产品获得境外上市许可

Core Viewpoint - The company, Huyou Pharmaceutical, has received marketing approvals for several of its products from regulatory authorities in Denmark, Germany, Uzbekistan, and Bangladesh, enhancing its international market presence and product pipeline [1] Group 1: Product Approvals - Huyou Pharmaceutical and its subsidiaries Seacross Pharma (Europe) Ltd. and Seacross Pharmaceuticals Ltd. have obtained marketing licenses for the following products: injectable paclitaxel (albumin-bound), injectable cyclophosphamide, paclitaxel injection, injectable zoledronic acid concentrated solution, and injectable azacitidine [1] - The approvals were granted by the Danish Medicines Agency, the German Federal Institute for Drugs and Medical Devices, the Uzbekistan Drug Regulatory Authority, and the Bangladesh Drug Regulatory Authority [1] Group 2: Market Impact - The recent approvals are expected to enrich the company's product pipeline in international markets, enhance its brand image, and facilitate the continuous expansion of its international business [1] - These developments lay a solid foundation for the sustainable growth of the company in the international market [1]